ラテラルフローアッセイの世界市場予測（～2023年）...市場調査レポートについてご紹介

TABLE OF CONTENTS

1 INTRODUCTION 26
1.1 OBJECTIVES OF THE STUDY 26
1.2 MARKET DEFINITION 26
1.3 MARKET SCOPE 27
1.3.1 MARKETS COVERED 27
1.3.2 YEARS CONSIDERED FOR THE STUDY 28
1.4 CURRENCY 28
1.5 LIMITATIONS 28
1.6 STAKEHOLDERS 29
2 RESEARCH METHODOLOGY 30
2.1 RESEARCH DATA 30
2.1.1 SECONDARY DATA 31
2.1.1.1 Key data from secondary sources 32
2.1.2 PRIMARY DATA 33
2.1.2.1 Key data from primary sources 34
2.1.2.2 Key industry insights 35
2.2 MARKET SIZE ESTIMATION 37
2.2.1 BOTTOM-UP APPROACH 37
2.2.2 TOP-DOWN APPROACH 38
2.3 MARKET BREAKDOWN & DATA TRIANGULATION 39
2.4 MARKET SHARE ESTIMATION 40
2.5 ASSUMPTIONS FOR THE STUDY 40
3 EXECUTIVE SUMMARY 41
4 PREMIUM INSIGHTS 45
4.1 LATERAL FLOW ASSAYS: MARKET OVERVIEW 45
4.2 LATERAL FLOW ASSAYS MARKET: DEVELOPED VS. DEVELOPING COUNTRIES/REGION 46
4.3 LATERAL FLOW ASSAYS MARKET: MAJOR COUNTRIES 47
4.4 GEOGRAPHIC MIX: LATERAL FLOW ASSAYS MARKET 48
4.5 LATERAL FLOW ASSAYS MARKET IN ASIA PACIFIC, BY APPLICATION AND COUNTRIES 49
 
5 MARKET OVERVIEW 50
5.1 INTRODUCTION 50
5.2 MARKET DYNAMICS: IMPACT ANALYSIS 50
5.2.1 MARKET DRIVERS 51
5.2.1.1 High prevalence of infectious diseases across the globe 51
5.2.1.2 Rapidly increasing geriatric population 53
5.2.1.3 Growing usage of home-based lateral flow assay devices 54
5.2.1.4 Growing demand for point-of-care testing 54
5.2.2 MARKET RESTRAINTS 55
5.2.2.1 Reluctance towards changing existing diagnostic practices 55
5.2.2.2 Implementation of excise duty on medical devices in the US 55
5.2.3 MARKET OPPORTUNITIES 55
5.2.3.1 Evolving applications of lateral flow assays 55
5.2.3.2 Rising demand for lateral flow assays in the food & beverage industry 56
5.2.4 CHALLENGES 57
5.2.4.1 Limited reimbursements for lateral flow assay products 57
6 INDUSTRY INSIGHTS 58
6.1 INTRODUCTION 58
6.2 INDUSTRY TRENDS 58
6.2.1 INTEGRATION OF MICROFLUIDIC TECHNOLOGY IN LATERAL FLOW ASSAYS 58
6.2.2 DEMAND FOR QUANTITATIVE RESULTS 59
6.2.3 RISING DEMAND FOR MULTIPLEXED LATERAL FLOW BIOSENSORS 59
6.3 VALUE CHAIN ANALYSIS 60
6.4 SUPPLY CHAIN ANALYSIS 61
6.5 REGULATORY ANALYSIS 62
6.5.1 NORTH AMERICA 63
6.5.2 EUROPE 64
6.5.3 ASIA 64
6.5.3.1 India 64
6.5.3.2 China 64
6.5.3.3 Japan 64
6.6 PARENT MARKETS ANALYSIS 65
 
7 LATERAL FLOW ASSAYS MARKET, BY PRODUCT 70
7.1 INTRODUCTION 71
7.2 KITS & REAGENTS 72
7.2.1 INCREASING DEMAND FOR POC TESTING IS DRIVING THE DEMAND FOR KITS AND REAGENTS IN THE LATERAL FLOW ASSAYS MARKET 72
7.3 LATERAL FLOW READERS 73
7.3.1 DIGITAL/MOBILE READERS 74
7.3.1.1 Growing awareness, technological advancements, and high accuracy are major factors driving the growth of the digital/mobile readers market. 74
7.3.2 BENCHTOP READERS 76
7.3.2.1 Lower diagnosis cost per patient is driving the benchtop readers market 76
8 LATERAL FLOW ASSAYS MARKET, BY APPLICATION 77
8.1 INTRODUCTION 78
8.2 CLINICAL TESTING 79
8.2.1 INFECTIOUS DISEASE TESTING 80
8.2.1.1 Mosquito-borne disease testing 82
8.2.1.1.1 Increasing incidence of dengue driving the growth of the lateral flow assay market for mosquito-borne testing 82
8.2.1.2 Influenza testing 84
8.2.1.2.1 Growing prevalence of influenza is expected to drive the influenza testing market. 84
8.2.1.3 Sexually transmitted infection testing 85
8.2.1.3.1 HIV Testing 86
8.2.1.3.1.1 Growing awareness about HIV POC testing are the major factors driving market growth. 86
8.2.1.3.2 HPV testing 88
8.2.1.3.2.1 Rising adoption of HPV testing is expected to drive the market during forecast period 88
8.2.1.3.3 Chlamydia testing 89
8.2.1.3.3.1 Consistantly growing incidence of chlamydia and rising awareness among patients is driving this market 89
8.2.1.3.4 Gonorrhea testing 91
8.2.1.3.4.1 The rising incidence of gonorrhea globally is expected to drive the lateral flow assays market during the forecast period. 91
8.2.1.3.5 Syphilis testing 92
8.2.1.3.5.1 The growing adoption of novel technologies supporting the growth of the lateral flow assays market for syphilis testing 92
8.2.1.3.6 Other sexually transmitted infection testing 94
8.2.1.4 Hepatitis 95
8.2.1.4.1 Nucleic acid hybridization-based lateral flow assays hold great potential in hepatitis testing market 95
8.2.1.5 Tuberculosis 96
8.2.1.5.1 Rising prevalence of the disease and a growing focus on early diagnosis and treatment of tuberculosis is expected to drive this market 96
8.2.1.6 Other infectious disease tests 97
8.2.2 CARDIAC MARKER TESTING 98
8.2.2.1 Troponin I and T testing 99
8.2.2.1.1 Introduction of high-sensitivity troponin assays is expected to drive this market during the forecast period 99
8.2.2.2 CK-MB testing 101
8.2.2.2.1 Growing application of lateral flow tests in acute myocardial injuries is expected to drive this market 101
8.2.2.3 BNP and NT-proBNP testing 102
8.2.2.3.1 Increasing demand for cardiac biomarker tests to detect heart stress and damage to drive the growth in this market 102
8.2.2.4 Myoglobin testing 103
8.2.2.4.1 Availability of new high-sensitivity cardiac troponin assays to restrict the growth of the routine myoglobin testing market 103
8.2.2.5 D-Dimer testing 104
8.2.2.5.1 The rising incidence of cardiovascular diseases globally is expected to drive the market for D-dimer tests 104
8.2.2.6 Other cardiac marker tests 105
8.2.3 PREGNANCY & FERTILITY TESTING 106
8.2.3.1 Pregnancy testing 108
8.2.3.1.1 Pregnancy testing is among well-established application areas for lateral flow assays, registering slower growth during the forecast period 108
8.2.3.2 Fertility testing 109
8.2.3.2.1 Rising infertility rates across the globe driving the demand for POC fertility testing kits. 109
8.2.4 CHOLESTEROL TESTING/LIPID PROFILE 110
8.2.4.1 The growing prevalence of obesity and CVD is the key factor driving market growth 110
8.2.5 DRUGS OF ABUSE TESTING 111
8.2.5.1 Technological advancements, rising public awareness, and growing focus on workplace drug testing is driving the drugs of abuse testing market 111
8.2.6 OTHER CLINICAL TESTS MARKET 112
8.3 VETERINARY DIAGNOSTICS 113
8.3.1 INFECTIOUS DISEASE OUTBREAKS (PARTICULARLY IN LARGE LIVESTOCK ANIMALS) IS DRIVING THE DEMAND FOR LATERAL FLOW TESTS 113
8.4 FOOD SAFETY & ENVIRONMENT TESTING 115
8.4.1 HIGH SENSITIVITY AND EASE OF USE DRIVING THE DEMAND FOR LATERAL FLOW ASSAYS FOR FOOD SAFETY TESTING 115
 
8.5 DRUG DEVELOPMENT & QUALITY TESTING 116
8.5.1 INCREASING FOCUS ON PRODUCT SAFETY AND QUALITY ASSURANCE IS DRIVING THE GROWTH OF THIS MARKET 116
9 LATERAL FLOW ASSAYS MARKET, BY TECHNIQUE 118
9.1 INTRODUCTION 119
9.2 SANDWICH ASSAYS 120
9.2.1 WIDE APPLICATIONS OF SANDWICH ASSAYS IN CLINICAL TESTING CONTRIBUTING TO THE LARGEST SHARE OF THIS SEGMENT 120
9.3 COMPETITIVE ASSAYS 121
9.3.1 HORMONE TESTING, DRUG TESTING, AND DRUGS OF ABUSE TESTING ARE PRIMARY APPLICATION AREAS OF COMPETITIVE ASSAYS 121
9.4 MULTIPLEX DETECTION ASSAYS 122
9.4.1 INCREASING ADOPTION OF MULTI-ANALYTE ASSAYS AMONG CLINICIANS TO DRIVE THE GROWTH OF THIS MARKET 122
10 LATERAL FLOW ASSAYS MARKET, BY END USER 123
10.1 INTRODUCTION 124
10.2 HOSPITALS & CLINICS 125
10.2.1 INCREASING USE OF POC TESTS AND FASTER DIAGNOSIS DRIVING ADOPTION OF LATERAL FLOW ASSAYS AMONG HOSPITALS & CLINICS 125
10.3 DIAGNOSTIC LABORATORIES 126
10.3.1 LABORATORY TESTING IS LARGELY PREFERRED OVER PROFESSIONAL SETTINGS FOR URINE AND BLOOD TESTING 126
10.4 HOME CARE 127
10.4.1 GROWING ACCEPTANCE OF HOME AND REMOTE MONITORING DRIVING THE GROWTH OF THE LATERAL FLOW ASSAYS MARKET FOR HOME CARE 127
10.5 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 129
10.5.1 INCREASING FOCUS ON PRODUCT SAFETY EXPECTED TO DRIVE THE GROWTH OF THE LATERAL FLOW ASSAYS MARKET AMONG PHARMACEUTICAL AND BIOTECH COMPANIES 129
10.6 OTHERS END USERS 130
11 LATERAL FLOW ASSAYS MARKET, BY REGION 131
11.1 INTRODUCTION 132
11.2 NORTH AMERICA 134
11.2.1 US 140
11.2.1.1 The US accounts for the largest share of the global lateral flow assays market 140
11.2.2 CANADA 145
11.2.2.1 The availability of research funding and implementation of favorable government initiatives is driving the market in Canada 145
11.3 EUROPE 150
11.3.1 GERMANY 156
11.3.1.1 Along with home care, growing number of the POC diagnostics centers driving the demand for lateral flow assays in Germany 156
11.3.2 FRANCE 161
11.3.2.1 Prevalence of age-related chronic diseases and infectious diseases is expected to drive the market growth in France 161
11.3.3 UK 166
11.3.3.1 Increasing incidence of chronic diseases and rising prevalence of obesity propelling the market growth in the UK 166
11.3.4 ITALY 171
11.3.4.1 Growing initiatives towards decentralization of medical services in Italy is contributing to the market growth in the country 171
11.3.5 SPAIN 176
11.3.5.1 Increasing focus of international organizations and domestic players toward the development of POC products in the country 176
11.3.6 REST OF EUROPE 181
11.4 ASIA PACIFIC 186
11.4.1 CHINA 192
11.4.1.1 Along with clinical diagnostics, the growing adoption of lateral flow assays in veterinary diagnostics and drug development expected to drive the market growth in China 192
11.4.2 JAPAN 197
11.4.2.1 Increasing prevalence of age-related illnesses, attributed to the growth in country’s geriatric population driving the growth of the lateral flow assays market in Japan 197
11.4.3 INDIA 202
11.4.3.1 Increasing prevalence of chronic disorders, growing healthcare concerns, and rising income levels is expected to propel the growth of this market 202
11.4.4 REST OF ASIA PACIFIC 207
11.5 LATIN AMERICA 212
11.5.1 INCREASING INCIDENCE OF CHRONIC DISEASES DRIVING THE DEMAND FOR LATERAL FLOW ASSAYS IN LATIN AMERICA 212
11.6 MIDDLE EAST & AFRICA 217
11.6.1 SIGNIFICANT SUPPORT FROM THE GOVERNMENTS AND GLOBAL FIRMS TOWARDS EXPANSION OF HEALTHCARE SERVICES IS DRIVING ADOPTION OF LATERAL FLOW ASSAYS IN THE AFRICAN REGION 217
 
12 COMPETITIVE LANDSCAPE 223
12.1 INTRODUCTION 223
12.2 PRODUCT PORTFOLIO ANALYSIS 224
12.3 GEOGRAPHICAL ASSESSMENT OF MAJOR PLAYERS IN THE LATERAL FLOW ASSAYS MARKET 225
12.4 MARKET SHARE ANALYSIS (2017) 226
12.5 COMPETITIVE SITUATIONS AND TRENDS 228
12.5.1 PRODUCT LAUNCHES 228
12.5.2 ACQUISITIONS 228
12.5.3 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS 229
12.5.4 EXPANSIONS 229
12.6 COMPETITIVE ASSESSMENT OF R&D EXPENDITURE 230
13 COMPANY PROFILES 231
(Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)*
13.1 ABBOTT LABORATORIES 231
13.2 F. HOFFMANN-LA ROCHE AG 236
13.3 DANAHER CORPORATION 240
13.4 SIEMENS AG 244
13.5 BECTON, DICKINSON AND COMPANY 248
13.6 BIOMÉRIEUX SA 252
13.7 BIO-RAD LABORATORIES, INC. 255
13.8 THERMO FISHER SCIENTIFIC INC. 258
13.9 QIAGEN N.V. 263
13.10 PERKINELMER INC. 266
13.11 HOLOGIC INC. 270
13.12 QUIDEL CORPORATION 273
13.13 MERCK KGAA 276
*Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.
14 APPENDIX 279
14.1 INSIGHTS OF INDUSTRY EXPERTS 279
14.2 DISCUSSION GUIDE 280
14.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 285
14.4 AVAILABLE CUSTOMIZATIONS 287
14.5 RELATED REPORTS 287
14.6 AUTHOR DETAILS 288